Compare FFWM & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FFWM | CBIO |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | United States |
| Employees | 485 | 44 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 557.8M |
| IPO Year | 2014 | N/A |
| Metric | FFWM | CBIO |
|---|---|---|
| Price | $5.90 | $18.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.17 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 4.3M | 305.9K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,373,000.00 | N/A |
| Revenue This Year | $56.34 | N/A |
| Revenue Next Year | $10.68 | $279.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.59 | $8.72 |
| 52 Week High | $6.72 | $27.41 |
| Indicator | FFWM | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 46.20 |
| Support Level | $5.44 | $10.83 |
| Resistance Level | $5.97 | $20.58 |
| Average True Range (ATR) | 0.19 | 2.40 |
| MACD | 0.03 | -0.34 |
| Stochastic Oscillator | 80.63 | 41.53 |
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.